Vijaya Diagnostic CentreBOM:543350 +3.17%83 EBITDA Margin % is 44.64% as of Mar. 2026, which is 3% above its 10-year median of 43.33. GuruFocus rates BOM:543350 with a GF Score™ of 83/100 and a GF Value™ of ₹1,181.14 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Vijaya Diagnostic Centre ranks better than 98.03% on this metric.
Vijaya Diagnostic Centre (BOM:543350) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vijaya Diagnostic Centre EBITDA Margin % Related Terms
Vijaya Diagnostic Centre EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543350 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Vijaya Diagnostic Centre's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vijaya Diagnostic Centre EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vijaya Diagnostic Centre's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vijaya Diagnostic Centre's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vijaya Diagnostic Centre (BOM:543350) has a EBITDA Margin % of 44.64% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vijaya Diagnostic Centre and its competitors. This is near median its historical median of 43.33. Over the past decade, Vijaya Diagnostic Centre's EBITDA Margin % has ranged from 40.07 to 46.77. According to the industry distribution chart, Vijaya Diagnostic Centre ranks #4 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 2%.
Is Vijaya Diagnostic Centre's EBITDA Margin % too high?
Vijaya Diagnostic Centre's current EBITDA Margin % of 44.64% is near median its 10-year median of 43.33. Over the past 10 years, this metric has ranged from a low of 40.07 to a high of 46.77. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Vijaya Diagnostic Centre's value of 44.64% is 792.8% above this industry median. Based on the distribution chart, Vijaya Diagnostic Centre ranks #4 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Vijaya Diagnostic Centre has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vijaya Diagnostic Centre's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vijaya Diagnostic Centre ranks #4 out of 203 companies for EBITDA Margin %. This places Vijaya Diagnostic Centre in the top 2% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.00. Vijaya Diagnostic Centre's value of 44.64% is 792.8% above this benchmark. Historically, Vijaya Diagnostic Centre's own EBITDA Margin % has ranged from 40.07 to 46.77 over the past decade. While the company's 10-year median is 43.33 vs. the industry median of 5.00, Vijaya Diagnostic Centre has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vijaya Diagnostic Centre's current EBITDA Margin % of 44.64% is 792.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vijaya Diagnostic Centre and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vijaya Diagnostic Centre's current EBITDA Margin % is 44.64%, which is near median its own 10-year median of 43.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vijaya Diagnostic Centre stock overvalued right now?
Based on GuruFocus' analysis, Vijaya Diagnostic Centre (BOM:543350) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,181.14, compared to a current price of ₹1,355.40 — trading 14.8% above its estimated fair value. The current EBITDA Margin % is 44.64%, which is near median its 10-year median of 43.33 and 792.8% above the Medical Diagnostics & Research industry median of 5.00. Vijaya Diagnostic Centre's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vijaya Diagnostic Centre (BOM:543350), the current EBITDA Margin % is 44.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vijaya Diagnostic Centre (BOM:543350) Overvalued in 2026?
Based on GuruFocus' analysis, Vijaya Diagnostic Centre stock appears to be overvalued.
The current stock price of ₹1,355.40 is trading 14.8% above its estimated GF Value™ of ₹1,181.14.
GuruFocus considers Vijaya Diagnostic Centre to be Modestly Overvalued.
Key valuation signals for BOM:543350:
EBITDA Margin %: 44.64% (near median its 10-year median of 43.33)
GF Value™: ₹1,181.14 vs. price of ₹1,355.40 (14.8% above fair value)
Industry Position: 792.8% above the Medical Diagnostics & Research median (#4 of 203)
No single metric tells the full story. See the BOM:543350 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vijaya Diagnostic Centre Ltd operates a diagnostic chain in Southern India. The company offers a one-stop solution for pathology and radiology testing services. It provides routine tests, specialized pathology tests, basic tests, and radiology tests. The company also offers a broad spectrum of customized health and wellness packages to its customers. The company's revenue comes from many diagnostic centers, where high-volume sales drive its earnings. The Company operates within India. The company's operations fall within a single business segment, which is Diagnostic Services.
83GF Score
Get the complete analysis for BOM:543350
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543350 has been successfully added to your 
